Engineered immune cells take aim at returning leukemia after transplant

NCT ID NCT03326921

First seen Nov 15, 2025 · Last updated Apr 29, 2026 · Updated 20 times

Summary

This early-stage study tests a new treatment for children and adults whose acute leukemia has come back or not responded after a donor stem cell transplant. The treatment uses specially engineered immune cells (T cells) from the original donor that are trained to recognize and attack a protein called HA-1 found on leukemia cells. The main goals are to see if these cells can be made and given safely, and to find the best dose. Up to 24 participants aged 0-80 with specific genetic markers will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.